Through the prevention and earlier detection of cancer.
Early detection saves lives.
Equalizing precision medicine.
Serving unmet clinical needs.
Disease doesn’t discriminate
Diagnostics shouldn’t either. Capsulomics is bridging the socio-economic gap by developing tests based on diverse global clinical data that can be made more accessible. Simply put: we’re helping a wider range of people beat cancer through earlier detection and prevention.
We are developing technologies to inform earlier detection and cancer prevention, leading to life-saving early interventions using proprietary epigenetic biomarker assays, methylation-specific PCR, diverse-population clinical studies, and data science. Our rigorous approach is built upon 30+ years of research and over $25M in research funding at Johns Hopkins University School of Medicine. Our initial tests focus on the earlier detection and prevention of the fastest growing malignancy in the United States: esophageal cancer.
Board of Directors
Capsulomics is the newest molecular diagnostics company to come out of the Johns Hopkins University Sidney Kimmel Comprehensive Cancer and is built upon 30+ years of research progress. Our leaders are experts in molecular biomarker assays who have the experience, expertise and drive to rapidly grow value.
Qubely – A Full-fledged Gutenberg Builder
Have questions? Get in touch with us today.
We’re building a world where life-saving cancer diagnostics is less invasive and more inclusive by developing affordable and accessible early detection technology that works for everyone, everywhere.
Copyright © 2021 Capsulomics